Nuclear thymidylate synthesis complex (dTMP-SC) (dTMP-SC)

The nuclear thymidylate synthesis complex (dTMP-SC) is a specialized multienzyme assembly that facilitates the de novo production of deoxythymidine monophosphate (dTMP) within the cell nucleus [NIH, PubMed]. It primarily consists of thymidylate synthase (TYMS), dihydrofolate reductase (DHFR), and serine hydroxymethyltransferase (SHMT1 or SHMT2α), which translocate from the cytoplasm to the nucleus during the S-phase of the cell cycle [Journal of Biological Chemistry, NIH]. This localization is critical for providing a concentrated pool of dTMP directly at the sites of DNA replication and repair, thereby preventing the misincorporation of uracil into the genome and ensuring high-fidelity DNA synthesis [NIH, ResearchGate]. The complex is a cornerstone of cancer pharmacology, as it is the primary target for widely used antimetabolite drugs like 5-fluorouracil and methotrexate [NIH, PubMed]. Inhibition of these enzymes leads to "thymineless death," a state of lethal DNA damage caused by nucleotide depletion [ResearchGate, MDPI]. Recent studies have identified that the assembly and nuclear import of this complex are regulated by SUMOylation and can be influenced by the PTEN tumor suppressor, making it a focal point for understanding drug resistance and developing next-generation oncology therapeutics [NIH, MDPI].

Other names

Nuclear thymidylate biosynthesis enzymesNuclear de novo thymidylate biosynthesis pathwaydTMP synthesis complexThymidylate synthesis multienzyme complexNuclear dTMP synthesis machinery

Inhibition of de novo dTMP synthesis, leading to deoxyribonucleotide triphosphate (dNTP) pool imbalance, uracil misincorporation, and thymineless death.